Edition:
United States

CymaBay Therapeutics Inc (CBAY.PH)

CBAY.PH on Philadelphia Stock Exchange

7.75USD
21 Jul 2017
Change (% chg)

$0.42 (+5.73%)
Prev Close
$7.33
Open
$7.19
Day's High
$7.89
Day's Low
$7.19
Volume
17,361
Avg. Vol
2,823
52-wk High
$7.89
52-wk Low
$1.48

CBAY.PH

Chart for CBAY.PH

About

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $323.58
Shares Outstanding(Mil.): 41.75
Dividend: --
Yield (%): --

Financials

  CBAY.PH Industry Sector
P/E (TTM): -- 213.75 15.85
EPS (TTM): -1.05 -- --
ROI: -112.83 -7.93 -8.31
ROE: -162.03 -9.29 -7.95

BRIEF-CymaBay announces pricing of public offering of common stock

* CymaBay announces pricing of public offering of common stock

Jul 19 2017

BRIEF-Cymabay announces proposed public offering of 10.0 mln common shares

* Cymabay Therapeutics Inc - anticipates using net proceeds from offering to fund ongoing development of seladelpar

Jul 17 2017

BRIEF-CymaBay announces positive interim results from low-dose phase 2 study of seladelpar

* CymaBay announces positive interim results from its ongoing low-dose phase 2 study of seladelpar in patients with primary biliary cholangitis

Jul 17 2017

BRIEF-Cymabay Therapeutics files for potential mixed shelf offering of up to $100 mln

* Cymabay Therapeutics Inc files for potential mixed shelf offering of up to $100 million - sec filing Source text (http://bit.ly/2q9MuN0) Further company coverage:

May 11 2017

BRIEF-Cymabay reports Q1 loss per share $0.20

* Cymabay reports first quarter 2017 financial results and provides corporate update

May 11 2017

BRIEF-CymaBay reports Q4 and year end 2016 financial results

* CymaBay reports fourth quarter and year end 2016 financial results

Mar 23 2017

BRIEF-Cymabay announces pricing of public offering of common stock

* Cymabay announces pricing of public offering of common stock

Feb 02 2017

BRIEF-CymaBay reports proposed public offering of common stock

* Anticipates using net proceeds from offering to fund ongoing development of seladelpar Source text for Eikon: Further company coverage:

Feb 01 2017

Earnings vs. Estimates